Eye scans may spot Alzheimer's early
NCT ID NCT03761381
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether special eye scans can detect signs of Alzheimer's disease and dementia. Researchers will use two non-invasive imaging devices to look for blood vessel changes and protein deposits in the retina. The study involves 20 participants, including people with mild dementia and healthy volunteers, to see if these eye changes match the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, non-invasive eye test to help diagnose Alzheimer's disease earlier.
- What could go wrong
- This is a very small, early-stage study (20 participants) that only looks for differences, not a treatment. The findings may not apply to everyone or lead to a reliable diagnostic tool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2018
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Dementia subjects will be recruited from the Layton Aging \& Alzheimer's Disease Clinic at Oregon Health \& Science University. Dementia-free subjects will be recruited from those currently being followed in the Layton Aging \& Alzheimer's Disease Center longitudinal aging study with MRI and amyloid PET imaging.
- Ages
-
55 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for dementia subjects: * Physician-confirmed diagnosis of probable Alzheimer's disease * Mild dementia, as defined by score of 20 or greater on the Mini-Mental State Exam, or score of 15 or greater on the Montreal Cognitive Assessment, or Clinical Dementia Rating Scale score of 1. * Age older than 55 years. * Able to comply with study procedures * Corrected visual acuity at least 20/400 in either eye. * Has a legally authorized representative who can sign study consent form and accompany the participant to the OCT study visit. Inclusion Criteria for dementia-free controls: * Age older than 55 years * Able to comply with study procedures * Able to maintain stable fixation for OCT imaging * Corrected visual acuity of at least 20/40 in either eye * Dementia-free, as defined by score of 24 or greater on the Mini-Mental Status Exam, or a score of 18 or greater on the Montreal Cognitive Assessment, or Clinical Dementia Rating of \<1.0. Exclusion Criteria for both dementia and dementia-free subjects: * Non-Alzheimer's disease related primary neurologic disease affecting the central nervous system (i.e. multiple sclerosis, Parkinson's disease) * Evidence on ophthalmological exam within the last year of other ocular diseases or pathology that would confound the assessment of dementia (e.g. glaucoma, diabetic or hypertensive retinal disease, amblyopia, etc.) * Media opacity such as cataract, corneal scar, or vitreous opacity that could interfere with retinal imaging. * Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation * Inability to maintain stable fixation for OCT imaging or provide informed consent * Spherical equivalent refractive error greater than +3 or -7 diopters, or astigmatism magnitude of greater than 2 diopters. * Diabetes for more than 10 years or hemoglobin A1C level of \> 10 within the 180 days prior to OCT scanning. * Uncontrolled hypertension. : SBP \> 170 or DBP \> 100 * Arrhythmia: irregular pulse, or heart rate not between 50 and 110 beats per minute * Pregnancy or breast feeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- A simple gel meets the Mouth's microscopic zoo
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Walking memory tests may reveal early Parkinson's clues